Overview
Welcome to our event "Strategies for Successful Technology Translations" taking place on July 4th, 2024. This event is organised by Singapore National Biofilm Consortium (SNBC) in partnership with SINERGY (Singapore Consortium for Synthetic Biology) and Biotech Connection Singapore.
Join us and learn the best practices and techniques for successful technology translation. Our event is perfect for anyone looking to enhance translation of microbial technologies and stay up-to-date with the latest trends in the biotech industry. The event is especially curated for spin-offs, start-ups and for anyone with tech offers and tech needs in this area.
Get ready for an insightful and informative event that will share more on the tips and tricks for translation of technology. See you there!
Schedule
Date: 04 Jul 2024, Thursday
Time: 3:30 PM - 6:00 PM (GMT +8:00) Kuala Lumpur, Singapore
Location: ACE Ideation Centre - Ayer Rajah Crescent Block 79, Level 1 JTC LaunchPad @ One-North Singapore , 139955
Speakers
Speaker's Profile:
Lee Jung Joon, Dr, Department of Biochemistry, Yong Soo Lin School of Medicine, NUS
Dr. Jungjoon K. Lee received his Ph.D. in chemistry from Stanford University in 2011 under the theme of Directed Evolution, and BA/MSci degrees in Natural Science (Chemistry) from the University of Cambridge in 2005. After his Ph.D, he worked in the Future Biotherapeutics department of Samsung Advanced Institute of Technology for three years and as a research scientist at the Seoul National University's Institute of Molecular Biology & Genetics for two years conducting research in CRISPR-Cas9. After which, he joined Toolgen, a biotech company focused on CRISPR-Cas technology in 2016 where he worked in the Platform development team and published a number of papers and patents related to the CRISPR platform. He is currently an Assistant Professor at the National University of Singapore.
Speaker's Profile:
Tarun Chopra, Dr, Director, Advanced Research Singapore, L'ORÉAL R&I; Joint Director, L’ORÉAL-SCELSE Joint Laboratory
Tarun has multi disciplinary expertise across multiple scientific disciplines including chemical biology, biotechnology, and microbiology. Prior to joining L’Oréal, Tarun spent 5 years in Switzerland as a post doctoral researcher at EPFL, Switzerland working towards understanding mechanisms of metabolic regulation in bacteria Prior to the EPFL, Tarun earned a Ph.D. in Chemical Biology from the National Institute of Immunology in India and also a M.Sc. in Chemistry from the Indian Institute of Technology in Delhi, India
Speaker's Profile:
Akbar Vahidi, Dr, CTO & Co-Founder at Allozymes
Dr Akbar Vahidi is a scientist-entrepreneur who received his PhD from the DEPARTMENT OF CHEMICAL & BIOMOLECULAR ENGIINERING in the National University of Singapore in 2015. He has a decade of experience in enzyme technology and biocatalysis, delivered several industrial projects to big pharma, food and biofuel companies during his career in academia. He was the lead researcher in an interdisciplinary team that invented Allozymes’ technology for faster and cheaper enzyme development. Akbar then started Allozymes as co-founder and CTO, where he is building next-generation synthetic biology platform and applying futuristic solutions to solve sustainable manufacturing problems by unlocking enzymes potential.
Moderator's Profile:
Michel Birnbaum, Mr , SCELSE ; Co-Founder & CEO OF MINDSIGNS HEALTH™ INC
Michel is currently Director of Entrepreneurship and Research Translation at NTU-SCELSE, working on technology commercialization via spinoffs and industry collaborations and partnerships, strategy and corporate development. He was responsible for the development and operations, from 2019-2022, of the Singapore National Biofilm Consortium and creating partnerships in the US, UK and EU. Michel was a lecturer for the MIT-SMART ACT program where he developed and taught the course “Lab to Market”. He is co-founder and CEO of Mindsigns Health™ Inc a software brain health platform spun out of NTU. He is also advisor to a number of healthcare spinoffs involved in anti-microbials to microbiomes. Michel has held board positions with a number of technology and healthcare growth companies internationally, operational advisory roles and has managed technology & healthcare IPOs on both European markets and NASDAQ as well as M&A and investments.
